IP Cases — 2024
6,517 decisions across all jurisdictions
Page 38 of 218 · 6,517 total
Fortinet, Inc. v.Croga Innovations Ltd.
Fortinet has filed a petition for inter partes review of Croga Innovations' U.S. Patent 10,601,780, asserting that all 20 claims are obvious over prior‑art firewalls and virtualization systems. The petition argues that discretionary denial is inappropriate and seeks institution of the IPR.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma has filed an IPR petition seeking cancellation of all 17 claims of U.S. Patent 10,632,069 covering budesonide orally dispersing tablets, arguing obviousness over Dohil, Grother and FDA guidance.
Nokia of America Corporation et al. v.Woodbury Wireless, LLC
Nokia, AT&T and T‑Mobile have filed an IPR petition seeking to invalidate Woodbury Wireless’s ’895 patent covering MIMO Wi‑Fi systems, arguing that the claims are obvious over the Lastinger publication and Sadowsky patent.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma has filed an IPR petition seeking cancellation of all 16 claims of Ellodi's 11,246,828 patent covering budesonide orally dispersing tablets, arguing obviousness over Dohil, Grother and FDA guidance.
Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.
Amazon has filed an IPR petition seeking cancellation of 22 claims of the ’887 patent, arguing they are obvious over a suite of prior‑art references covering mobile‑device virtualization and remote desktop technologies.
Fortinet, Inc. v.Croga Innovations Ltd.
Fortinet's attempt to invalidate Croga Innovations Ltd.'s patent on network security claims was denied by the PTAB. The Board found that Fortinet failed to demonstrate obviousness over prior art, specifically Delco and Adams. This denial maintains the validity of key virtualization and firewall technology for Croga.
Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.
Amazon's IPR petition against B.S.D. Crown, Ltd. was denied after the Board maintained its finding that Petitioner lacked a reasonable likelihood of prevailing on the merits. The denial hinged on the Board adopting a conjunctive construction for key claim terms and finding no prior art disclosed all necessary components.
Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.
Amazon's request for Director Review regarding the institution denial of patent 8934887 was denied. Although the Board misapprehended one figure, the Panel upheld the conjunctive claim construction based on the full intrinsic record.
Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.
Amazon's attempt to invalidate B.S.D. Crown's '887 patent failed before the PTAB, with the Board denying the IPR petition. The denial hinged on Amazon failing to adequately address a key claim construction—the conjunctive nature of an element related to hardware action.
Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.
The Director granted review and vacated the denial of institution in an Amazon v. B.S.D. Crown IPR, remanding the case for further proceedings to resolve a disputed claim term.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.
Samsung Electronics Co., Ltd. et al. v.Netlist, Inc.
Samsung Electronics successfully secured institution in this IPR, challenging all 20 claims of Netlist's patent (11880319) based on obviousness and anticipation. The Board found that the Petitioner demonstrated a reasonable likelihood of unpatentability over various combinations of prior art, including Hazelzet, JEDEC, Buchmann, Wang, and Kim. This decision sets a strong precedent for challenging memory module initialization claims using industry standards and technical literature.
Levi Strauss & Co v.Ashok Woven Labels And Ors
The plaintiff, Levi Strauss & Co., filed a suit seeking permanent injunction against the defendants for infringing its trademarks, specifically 'LEVI's' and 'LEVI'S PREMIUM'. The plaintiff alleged that the defendants were manufacturing and selling counterfeit labels and goods using the protected marks. The court ultimately decreed the suit in favor of the plaintiff.
Promoshirt Sm. S.A. v.The Registrar Of Trade Marks
The Delhi High Court ruled in favor of Promoshirt Sm. S.A., directing The Registrar of Trade Marks to renew and restore a trademark application (No. 1355453). The petitioner argued that the delay in issuing the registration certificate, which occurred two years after the validity expired, prevented timely renewal. Citing precedent, the Court held that the proprietor should not be penalized for procedural lapses by the Registry, mandating the issuance of the renewal certificate and necessary database corrections.
Promoshirt Sm. Pvt. Ltd. v.The Registrar Of Trade Marks
The Delhi High Court ruled in favor of Promoshirt Sm. Pvt. Ltd., directing the Registrar of Trade Marks to restore and renew a trademark registration (No. 1150198). The petitioner argued that the delay in issuing the certificate, coupled with failure to serve mandatory renewal notices (O-3 Notice), prevented them from renewing their mark despite its initial validity period expiring. Citing precedent, the Court held that the proprietor should not be penalized for administrative lapses by the Registry, mandating the restoration and subsequent renewal of the trademark.
V.P. Nandakumar and Manappuram Finance Limited v.Jayashree
In a dispute over the 'MANAPURAM' trademark, V.P. Nandakumar and Manappuram Finance Limited successfully reached a settlement with Jayashree before the Madras High Court. The parties agreed that the Petitioner has prior rights to the mark and that the Respondent will cancel her existing registration (No. 5109630) and transfer associated domain names within ten days. This compromise resolves the petition seeking removal of the infringing trademark entry.
Kenny Ramanand and Balasubramaniam V. v.Rehan Talat Khan and N.S. Sangolli
Kenny Ramanand and Balasubramaniam V. filed an application to set aside an arbitration award dated 10-01-2012. The dispute arose from a partnership in M/s Gambaz Foods International, involving allegations of breach of trust, financial misappropriation, and trademark disputes related to the brand 'Prawnto'.
Mr.Rahul Bagga v.The Controller of Patent
The petitioner filed a writ petition seeking to quash an abandonment order related to his patent application (No. 202041009246). The petitioner argued that he was unable to upload the response to the First Examination Report on the deadline due to technical/server errors on the respondent's website. The court found merit in this claim and ordered the abandonment quashed, directing the respondent to accept the response.
Dehns (Application under Rule 262.1(b) RoP in Sanofi-Aventis v.Amgen revocation proceedings)
Dehns, a law firm representing clients before the Unified Patent Court, applied under Rule 262.1(b) RoP for access to all written pleadings and evidence from a concluded revocation action between Sanofi-Aventis entities and Amgen concerning European patent EP 3 666 797. The Judge-rapporteur granted access to the written pleadings and evidence (subject to redaction of personal data) but rejected the request for other procedural documents that did not qualify as written pleadings or evidence.
Dehns (Application under Rule 262.1(b) RoP in Regeneron Pharmaceuticals Inc. v.Amgen, Inc.)
Dehns, a firm of UPC representatives, applied under Rule 262.1(b) of the Rules of Procedure for access to all written pleadings and evidence lodged in revocation and counterclaim for revocation proceedings between Regeneron Pharmaceuticals Inc. and Amgen, Inc. concerning European patent EP 3 666 797. The Court of First Instance granted access to the written pleadings and evidence, applying the general principles established by the Court of Appeal in Ocado/Autostore, but rejected the request for other documents that did not qualify as written pleadings or evidence.
Dehns (Application under Rule 262.1(b) RoP in Sanofi-Aventis v.Amgen revocation proceedings)
Dehns, a firm of UPC representatives, applied under Rule 262.1(b) of the Rules of Procedure for access to all written pleadings and evidence lodged in a revocation action between Sanofi-Aventis entities and Amgen concerning European patent EP 3 666 797, which had been decided on 16 July 2024. The Court of First Instance (Central Division, Munich) granted access to the written pleadings and evidence after redaction of personal data, but rejected the request in respect of other listed documents (such as administrative letters, formal checks, and proof of payment) that did not qualify as written pleadings or evidence within the meaning of Rule 262.1(b).
Amazon.com, Inc. et al. v.Nokia Technologies Oy
Amazon and Nokia have settled their dispute over a Nokia wireless‑technology patent and jointly moved to terminate the IPR, requesting that the settlement be kept confidential.
Amazon.com, Inc. et al. v.Nokia Technologies Oy
Amazon and Nokia settled their dispute over U.S. Patent 9,571,833 and jointly moved to terminate the inter partes review.
Amazon.com, Inc. et al. v.Nokia Technologies Oy
Amazon and Nokia filed a joint motion to terminate the IPR on patent 9,571,833 after instituting the review. The Board granted the termination and partially approved confidentiality of the settlement documents.
MediaTek, Inc. et al. v.Redstone Logics LLC
MediaTek has filed an IPR petition seeking to invalidate 12 claims of Redstone Logics’ ’339 patent covering multi‑core processor voltage and clock management, arguing obviousness over several prior‑art references and urging the Board to institute the review.
Amazon.com, Inc. et al. v.Nokia Technologies Oy
Amazon has filed an IPR petition challenging Nokia’s 9,571,833 patent on HEVC motion‑vector prediction, arguing obviousness over Rusert/Zheng and Nakamura/WD4 and disputing the examiner’s allowance.
Innoscience America, Inc. et al. v.Infineon Technologies Americas Corp.
Innoscience America petitions the PTAB to institute an IPR against Infineon's 9,070,755 transistor patent, seeking cancellation of all 14 claims on the basis of anticipation and obviousness over Fujishima and related prior art. The petition argues that discretionary denial is improper and requests the Board find the claims unpatentable.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.